[Federal Register: October 6, 1999 (Volume 64, Number 193)] [Notices] [Page 54336-54338] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr06oc99-109] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, DHHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage [[Page 54337]] for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852- 3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Adenoviral Vector Expressing a SV4OT Antigen Antisense RNA David S. Schrump, Z. Sheng Guo, Ishrat Wahseed (NCI) Serial No. 60/124,776 filed 17 Mar 1999 Licensing Contact: Richard U. Rodriguez; 301/496-7056 ext. 287; e-mail: rr154z@nih.gov Desired nucleic acid sequences with therapeutic potential may be introduced into mammalian cells using appropriate vectors. Antisense technology is well known in the art and describes a mechanism whereby a nucleic acid comprising a nucleotide sequences, which is in a complementary, ``antisense'' orientation with respect to a coding or ``sense'' sequence of an endogenous gene, is introduced into a cell, whereby a duplex forms between the antisense sequence and its complementary sense sequence. The formation of this duplex results in inactivation of the endogenous gene. The present invention describes a method of treatment of cancer by administering a replication-deficient recombinant adenovirus comprising a nucleic acid that encodes an antisense rebonucleic acid to the SV40 T antigene. In addition, it provides methods for reducing the level of expression of SV40 T antigen, induction of apoptosis, effecting cell growth arrest, reducing the levels of proto-oncogene expression, unregulating pro-apoptotic proteins, maintaining normal levels of functional p53, and maintaining normal levels of functional Rb, p107, and p130. The types of cancers contemplated by this invention include all cancers that express SV40 T antigen. Aspartic Protease Inhibitors, Compositions, and Associated Therapeutic methods Ramnarayan S. Randad, John W. Erickson, Michael A. Eissenstat, Lucyna Lubkowska (NCI) Serial No. 60/114,868 filed 06 Jan 1999 Licensing Contact: John Peter Kim; 301/496-7056 ext. 264; e-mail: jk141n@nih.gov The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). Drug-resistance is a critical factor contributing to the gradual loss of clinical benefit to treatments for HIV infection. Accordingly, combination therapies have further evolved to address the mutating resistance of HIV. However, there has been great concern regarding the apparent growing resistance of HIV strains to current therapies. The subject invention provides compounds which may serve as therapeutic candidates for inhibition of HIV-1 PR (protease) and thus serve in controlling AIDS, as well as having anti-malarial properties. These compounds may be used in combination with other protease inhibitors or inhibitors of HIV-1 reverse transcriptase, especially in patients who have developed resistance to other HIV protease inhibitors. These inhibitors have high potency, lower molecular weight, and lower lipophilicity than previous compounds, as well as a better profile towards drug resistant mutant strains of HIV. 2,5-Diamino-3,4-Disubstituted-1,6-Diphenylhexane Isosteres Comprising Benzamide, Sulfonamide and Anthranilamide Subunits and Methods of Using Ramnarayan S. Randad and John W. Erickson (NCI) Serial Nos. 09/039,669 and 09/039,670 filed 16 Mar 1998; Serial No. 08/ 359,612 filed 20 Dec 1994 Licensing Contact: John Peter Kim; 301/496-7056, ext. 264; e-mail: jk141n@nih.gov The human immunodeficiency virus (HIV) is the causative agent of acquired immunodeficiency syndrome (AIDS). Drug-resistance is a critical factor contributing to the gradual loss of clinical benefit to treatments for HIV infection. Accordingly, combination therapies have further evolved to address the mutating resistance of HIV. However, there has been great concern regarding the apparent growing resistance of HIV strains to current therapies. The subject invention provides for treatment and prevention of HIV infection and/or AIDS. The invention provides for 2,5-diamino-3,4- disubstituted-1,6-diphenylhexane (DAD) isosteres comprising benzamide, sulfonamide, and anthranilamide subunits; a pharmaceutical composition comprising such compounds; a method of using such compounds to treat retroviral, specifically HIV and more specifically HIV-1 and HIV-2, infections in mammals, particularly humans; a method of synthesizing asymmetric DAD isosteres comprising benzamide, sulfonamide, and anthranilamide subunits; and a method of using such compounds to assay new compounds; for antiretroviral activity. Novel Tumor Necrosis Factor Family Member, DRL, and Related Compositions and Methods MJ Lenardo, J Wang, Di Jiang (NIAID) Serial No. 60/106,976 filed 04 Nov 1998 Licsening Contact: Susan S. Rucker; 301/496-7056 ext. 245; e-mail: sr156v@nih.gov The invention described and claimed in this patent application relates the isolation, cloning and characterization of a ligand which belongs to the TNF family of cytokines. This ligand, named DRL (also known as APRIL and TNFSF13), is a type II membrane protein of 250 amino acids. The gene encoding DRL is found on the short arm of chromosome 17 at 17 p11.2-12. Soluble DRL can be obtained by preparing a DRL-IgG fusion protein utilizing the extracellular domain of DRL. DRL has been demonstrated to play a significant role in T cell activation and is able to induce crosslinking of the T cell receptor. It is also capable of inducing T cell proliferation. These results suggest that DRL may be a target to be exploited in the treatment of conditions related to inappropriate T cell activation such as autoimmune diseases, tissue rejection and graft vs. host disease. Methods and Compositions of Chemokine-Tumor Antigen Fusion Proteins as Cancer Vaccines Larry W. Kwak, Arya Biragyn (NCI) U.S. Provisional Patent Application 60/077,745 filed 12 Mar 1998 (corresponding to PCT/US99/05345 filed 12 Mar 1999) Licensing Contact: Elaine Gese; 301/496-7056 ext. 282; e-mail: 3g46t@nih.gov The current invention embodies a broad range of fusion proteins, each of which consists of a chemokine and a tumor or viral antigen. Administration of these fusion proteins, or a nucleic acid encoding the fusion protein, elicits a specific and potent in vivo immune response directed against the antigen, thereby effectively inhibiting the growth of cells expressing that antigen. The fusion proteins or DNA vaccines therefore represent potential vaccines for use against cancer and also against human immunodeficiency virus (HIV) infection. [[Page 54338]] Dated: September 27, 1999. Jack Spiegel, Director, Division or Technology Development and Transfer, Office of technology Transfer, National Institutes of Health. [FR Doc. 99-25952 Filed 10-5-99; 8:45 am] BILLING CODE 4140-01-M